|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 81 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 82 | 2019 | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K.; Uitdehaag, B. M. | Journal Contribution | M |
| 83 | 2019 | Effectiveness and safety of Tetrahydrocannabinol - Cannabidiol Oromucosal spray in Belgian patients with multiple sclerosis spasticity: a retrospective data collection | POPESCU, Veronica; Vos, C.; van Dael, V.; Raeymaekers, G.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 84 | 2019 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P. | Journal Contribution | M |
| 85 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 86 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 87 | 2019 | Therapeutic lag in relapsing multiple sclerosis | ROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T. | Journal Contribution | M |
| 88 | 2019 | Predicting long-term sustained disability progression in multiple sclerosis | SHARMIN, Sohely; Malpas, C.; Horakova, D.; Havrdova, E. K.; Izquierdo, G.; Eichau, S.; Trojano, M.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Grammond, P.; Sola, P.; Ferraro, D.; Terzi, M.; Hupperts, R.; Alroughani, R.; Boz, C.; Shaygannejad, V.; Van Pesch, V.; Cartechini, E.; Kappos, L.; Lechner-Scott, J.; Bergamaschi, R.; Turkoglu, R.; Solaro, C.; Ramo-Tello, C.; Iuliano, G.; Granella, F.; VAN WIJMEERSCH, Bart; Spitaleri, D.; Bolanos, R. F.; Slee, M.; McCombe, P.; Prevost, J.; Ampapa, R.; Ozakbas, S.; Sanchez-Menoyo, J. L.; Soysal, A.; Vucic, S.; Petersen, T.; Verheul, F.; Butler, E.; Hodgkinson, S.; Sidhom, Y.; Gouider, R.; Butzkueven, H.; Kalincik, T. | Journal Contribution | M |
| 89 | 2019 | IgD(-)CD27(-) double negative B cells of multiple sclerosis patients have a pro-inflammatory migratory phenotype and function | BECKERS, Lien; Diaz, G. Montes; Villar, L. M.; VAN WIJMEERSCH, Bart; SOMERS, Veerle; FRAUSSEN, Judith | Journal Contribution | M |
| 90 | 2019 | A pilot study of the effects of running training on visuospatial memory in MS: A stronger functional embedding of the hippocampus in the default-mode network? | Huiskamp, Marijn; MOUMDJIAN, Lousin; VAN ASCH, Paul; POPESCU, Veronica; Schoonheim, Menno Michiel; Steenwijk, Martijn D.; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Geurts, Jeroen J. G.; FEYS, Peter; Hulst, Hanneke E. | Journal Contribution | A1 |
| 91 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 92 | 2019 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings | Barclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; de Seze, Jerome; Dela Cruz, Dionisio; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 93 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 94 | 2019 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis | Meuth, Sven G.; Brandes, David; Carraro, Matthew; Comi, Giancarlo; Mao-Draayer, Yang; Izquierdo, Guillermo; Kim, Ho Jin; Pardo, Gabriel; Sharrack, Basil; Tornatore, Carlo; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Jacobs, Alan; Chung, Luke; Daizadeh, Nadia; Wiendl, Heinz | Journal Contribution | M |
| 95 | 2019 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | M |
| 96 | 2019 | Neuromyelitis Optica in Flanders: an epidemiological study | Blomme, L.; MOONS, Lynn; Noels, S.; Laureys, G.; VAN WIJMEERSCH, Bart; Crols, R.; DE KLIPPEL, Nina; Van de Velde, K.; Willekens, B. | Journal Contribution | M |
| 97 | 2018 | Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study) | VAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C.; Selmaj, K. | Journal Contribution | M |
| 98 | 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 99 | 2018 | Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extension | Wiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 100 | 2018 | Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension | VAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H. | Journal Contribution | M |
Loading...
5
0
5
0
false